Biogen Inc. (LON:0R1B)
London · Delayed Price · Currency is GBP · Price in USD 128.53
-1.27 (-0.98%)
At close: Aug 11, 2025
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
959.48K GBP
Profits / Employee
146.89K GBP
Market Cap
13.99B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Oxford Nanopore Technologies | 1,382 |
| HUTCHMED (China) | 1,811 |
Biogen News
- 1 day ago - Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - GlobeNewsWire
- 1 day ago - Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Business Wire
- 10 days ago - Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio - Seeking Alpha
- 12 days ago - Biogen raises 2025 EPS guidance to $15.50-$16 as new launches drive 7% revenue growth - Seeking Alpha
- 12 days ago - Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Biogen Inc. 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 12 days ago - BIIB Earnings: Highlights of Biogen’s Q2 2025 results - AlphaStreet
- 12 days ago - Earnings Snapshot: Biogen tops Q2 estimates, raises FY EPS outlook - Seeking Alpha